Ariad Announces Data Presentations At American Society of Hematology Meeting

~Final report from Phase 1 study of ponatinib includes approximately five-year median follow-up; Major Molecular Response (MMR) rate was 56 percent

~Pooled Phase 1 and PACE analysis of CP-CML patients with T315I shows 83 percent estimated to maintain major cytogenetic response at four years

CAMBRIDGE, Mass. & SAN DIEGO--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of clinical and translational studies on Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). These data were featured in an oral and two poster presentations at the 57th Annual Meeting of the American Society of Hematology (ASH) taking place in San Diego.

“The data presented at ASH include the final report from the Phase 1 trial of ponatinib, with maximum follow-up of more than 7.5 years and median follow-up approaching five years that demonstrated ongoing cytogenetic and molecular responses. A separate study of CP-CML patients with the T315I mutation demonstrated a 72 percent probability of overall survival at 4.5 years among these patients who, prior to ponatinib, had no approved targeted treatment options and had a median survival of less than two years,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. “In addition, an oral presentation on studies in Ph+ ALL patients provides important new data on the molecular basis for Iclusig’s activity in these patients.”
MORE ON THIS TOPIC